Rocket Pharmaceuticals, Inc. (RCKT) Stock

Rocket Pharmaceuticals, Inc. (RCKT) is a Healthcare stock trading at $3.34 (as of 2026-06-18), with a market capitalization of $335.22M and a trailing P/E of -1.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Rocket Pharmaceuticals, Inc. develops gene therapies for rare diseases, including clinical programs using ex vivo lentiviral vectors for Fanconi anemia, leukocyte adhesion deficiency type I, and pyruvate kinase deficiency, as well as an in vivo AAV program for Danon disease. It conducts research and development across these programs and operates through its subsidiaries.

Valuation — source: SEC EDGAR (first-party)

Price	$3.34
Market Cap	$335.22M
P/E Ratio	-1.6
EV / EBITDA	-1.4
Price / Book	1.41
DCF Value (model)	$-29.14
DCF Upside vs Price	-972.5%

Profitability & Growth — source: SEC EDGAR

Revenue (TTM)	$0.00
Return on Equity	-88.0%
Current Ratio	6.12

Financial Health — source: SEC EDGAR

Altman Z-Score

-3.74 (distress)

Valuation vs Sector & Industry

Stock P/E	-1.6
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-107.9%
vs Industry	-109.6%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures

Top Institutional Holder	RTW INVESTMENTS, LP ($63.32M)
Institutional Holders Tracked	10

Company

Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Gaurav D. Shah
Employees	299
Country	US
IPO Date	2015-02-18

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• Altimmune, Inc. (ALT)
• Keros Therapeutics, Inc. (KROS)
• Tectonic Therapeutic, Inc. (TECX)
• Rezolute, Inc. (RZLT)
• Nature's Sunshine Products, Inc. (NATR)
• Palisade Bio, Inc. (PALI)
• enGene Holdings Inc. (ENGN)
• Aclaris Therapeutics, Inc. (ACRS)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.